EUVIMEDEUVIMED entdecken
Crossref

Efficacy of Immune Checkpoint Inhibitors in Postoperative Recurrence of Wild-type EGFR Non-Small Cell Lung Cancer

Yoshito Imamura, Taketo Kato, Yuji Nomata, Shoji Okado, Hiroki Watanabe, Yuta Kawasumi, Keita Nakanishi, Yuka Kadomatsu, Harushi Ueno, Shota Nakamura, Tetsuya Mizuno, Tetsunari Hase und 4 weitere

Anticancer Research · 2024

DOI: 10.21873/anticanres.17165 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2024. Verfasst von Yoshito Imamura und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Immune Checkpoint Inhibitors, ErbB Receptors.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: Immune checkpoint inhibitors (ICIs) have been widely used in the treatment of non-small cell lung cancer (NSCLC), but specific outcomes of ICIs treatment among patients with postoperative recurrence of NSCLC remain unclear. The objective of the study was to compare the efficacy of ICIs and chemotherapy with conventional chemotherapy only in patients with postoperative recurrence of epidermal growth factor receptor (EGFR) wild-type NSCLC. PATIENTS AND METHODS: A retrospective analysis was performed on patients who underwent anatomical lung resection at the Nagoya University Hospital and were treated for postoperative recurrence of wild-type EGFR NSCLC. This study evaluated the prognosis for postoperative recurrence, including ICIs treatment and other clinicopathological factors. RESULTS: Of the 83 patients included in the analysis, 20 patients underwent chemotherapy and 63 patients underwent chemotherapy combined with ICIs. The combination of ICIs and chemotherapy significantly prolonged survival after recurrence (median survival: 33.1 months vs. 22.0 months, p=0.01). In the ICIs group, no significant differences in survival were detected between patients with different programmed death ligand 1 (PD-L1) status (Tumor Proportion Scores:

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsImmune Checkpoint InhibitorsErbB ReceptorsNeoplasm Recurrence, LocalHumansMaleFemaleAgedMiddle AgedRetrospective StudiesAged, 80 and overPrognosisAdultTreatment Outcome

Stichwörter der Autor:innen

Immune checkpoint inhibitorsepidermal growth factor receptornon-small cell lung cancerpostoperative recurrenceprogrammed death ligand 1

Substanzen

Immune Checkpoint InhibitorsErbB ReceptorsEGFR protein, human

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Department of Thoracic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan; tkato@med.nagoya-u.ac.jp.
  • Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Department of Public Health and Health Systems, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Zitieren

APA

Imamura, Y., Kato, T., Nomata, Y., Okado, S., Watanabe, H., Kawasumi, Y., Nakanishi, K., Kadomatsu, Y., Ueno, H., Nakamura, S., Mizuno, T., Hase, T., Tanaka, I., Ishii, M., Yatsuya, H., & Chen-Yoshikawa, T. F. (2024). Efficacy of Immune Checkpoint Inhibitors in Postoperative Recurrence of Wild-type EGFR Non-Small Cell Lung Cancer. Anticancer Research. https://doi.org/10.21873/anticanres.17165

Vancouver

Imamura Y, Kato T, Nomata Y, Okado S, Watanabe H, Kawasumi Y, et al. Efficacy of Immune Checkpoint Inhibitors in Postoperative Recurrence of Wild-type EGFR Non-Small Cell Lung Cancer. Anticancer Research. 2024. doi:10.21873/anticanres.17165

BibTeX
@article{Imamura2024,
  author = {Imamura, Yoshito and Kato, Taketo and Nomata, Yuji and Okado, Shoji and Watanabe, Hiroki and Kawasumi, Yuta and Nakanishi, Keita and Kadomatsu, Yuka and Ueno, Harushi and Nakamura, Shota and Mizuno, Tetsuya and Hase, Tetsunari and Tanaka, Ichidai and Ishii, Makoto and Yatsuya, Hiroshi and Chen-Yoshikawa, Toyofumi Fengshi},
  title = {Efficacy of Immune Checkpoint Inhibitors in Postoperative Recurrence of Wild-type EGFR Non-Small Cell Lung Cancer},
  journal = {Anticancer Research},
  year = {2024},
  doi = {10.21873/anticanres.17165}
}
Kostenlos starten →